eligibility_summary
Adults ≥18 with consent, ECOG ≤1, stage IV esophagogastric adenocarcinoma after ≥1 platinum+fluoropyrimidine line (adjuvant counts if relapse ≤6 mo), measurable disease, adequate organs, ≥12‑wk life expectancy, willing for liquid biopsy/contraception. Exclude: MSI‑h/dMMR PD‑1–naive, prior topo‑I (irinotecan), hypersensitivity, active 2nd cancer, untreated/symptomatic CNS mets, major cardiac disease, IBD/GI perforation, serious infection, active HBV/HCV or HIV viremia, recent trials/therapy, unresolved ≥G2 AEs, pregnancy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase Ib/II, single-arm trial in metastatic esophagogastric adenocarcinoma testing sacituzumab govitecan (Trodelvy), a TROP‑2–targeting antibody‑drug conjugate (humanized anti‑TROP‑2 IgG1) linked to SN‑38, the active metabolite of irinotecan (topoisomerase I inhibitor). Dosing: 10 mg/kg IV on days 1 and 8 of a 21‑day cycle, up to 12 months. Mechanism: antibody binds TROP‑2 on tumor cells, internalizes, and releases SN‑38 to inhibit topoisomerase I, causing DNA damage/apoptosis, the membrane‑permeable payload may confer a bystander effect. Targets/pathways: TROP‑2–expressing epithelial cancer cells, topoisomerase I/DNA replication. Primary endpoint: ORR, subgroup analyses by TROP‑2 expression.